The Queensland Amyloidosis Centre is actively pursuing research to improve the diagnosis and management of patients with amyloidosis. Current research projects include:

• Fluorine-18-labelled florbetaben positron emission tomography to monitor cardiac amyloidosis. This study will see if PET scanning can be used to better monitor patients with cardiac amyloidosis.
• AT-01 CT-PET to diagnose and monitor all types of amyloidosis. This study will assess the world’s first scan to quantify amyloid deposition in all organs of the body.
• Laser capture microdissection and tandem mass spectrometry to diagnose amyloidosis subtype from formalin-fixed paraffin-embedded tissue biopsy samples. This study aims to optimise this diagnostic test and introduce it as an accredited assay for all Australians.
• Clinical trials of novel therapies (belantamab and etentamig) in the initial treatment of AL amyloidosis.
• Clinical trials of novel therapies (anti-fibril monoclonal antibodies, RNA knockdown therapies, CRISPR-based therapy) in the treatment of ATTR amyloidosis.
• Research to determine optimal early response criteria in AL amyloidosis.
• Development of mRNA vaccine to treat AL amyloidosis.

Publications.

• Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials. Wechalekar AD, Dispenzieri A, Sanchorawala V, Kastritis E, Bhutani D, Bianchi G, et al. J Clin Oncol. 2026:JCO2600755.

• Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis. Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Blood. 2026.

• Comparative evaluation of free light chain assays in AL amyloidosis: Performance of Sebia versus Freelite and N-Latex. Zhao F, Pretorius C, Mollee P. Pract Lab Med. 2026;49:e00519.

• An Australian Amyloidosis Network analysis of Australian patients with immunoglobulin light chain amyloidosis treated with bortezomib-based chemotherapy. Gibbons A, Chakravorty L, Sidiqi H, Ting S, Kwok F, Wisniowski B, et al. Intern Med J. 2026;56(4):582–8.

• Wild-Type Transthyretin-Related Amyloidosis in Kindreds: A Play of Chance or New Epiphenomenon? Kang K, Mollee P, Booth D, Korczyk D. Heart Lung Circ. 2026;35(3):e25–e8.

• A collaborative approach to amyloidosis and a multidisciplinary care framework – position statement from the International Society of Amyloidosis. Sanchorawala V, Wechalekar A, Mollee P, Sekijima Y, Maurer MS, Leung N, et al. Amyloid. 2025;32(4):303–8.
• Visualizing amyloidosis: the role of radionuclide imaging in systemic amyloidosis. Ranjit Anderson N, Dorbala S, Mollee P. Blood. 2025;146(10):1157–62.

• Transthyretin Cardiac Amyloidosis in Australia and New Zealand-A Multi-Site Snapshot for 2022. Geenty P, Davidson N, Gorrie N, Bart N, Baumwol J, Sutton T, et al. Heart Lung Circ. 2025;34(1):48–57.

• Improving care for systemic light-chain amyloidosis patients: is a multidisciplinary approach best? Ranjit Anderson N, Korczyk D, Mollee P. Expert Rev Hematol. 2024;17(9):567–79.

• 2024 Australia-New Zealand Expert Consensus Statement on Cardiac Amyloidosis. Bart NK, Fatkin D, Gunton J, Hare JL, Korczyk D, Kwok F, et al. Heart Lung Circ. 2024;33(4):420–42.
• Screening for and diagnosis of monoclonal gammopathy. Chong YP, Lim SM, Loh TP, Mollee P, Wijeratne N, Choy KW. J Clin Pathol. 2023;76(11):727–33.

• Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy. Obici L, Ajroud-Driss S, Lin KP, Berk JL, Gillmore JD, Kale P, et al. Neurol Ther. 2023;12(5):1759–75.

• Cardiac “hypertrophy” phenotyping: differentiating aetiologies with increased left ventricular wall thickness on echocardiography. Ferkh A, Tjahjadi C, Stefani L, Geenty P, Byth K, De Silva K, et al. Front Cardiovasc Med. 2023;10:1183485.

• Current approaches to the diagnosis and management of amyloidosis. Taylor MS, Sidiqi H, Hare J, Kwok F, Choi B, Lee D, et al. Intern Med J. 2022;52(12):2046–67.

• Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Adams D, Tournev IL, Taylor MS, Coelho T, Plante-Bordeneuve V, Berk JL, et al. Amyloid. 2023;30(1):1–9.

• Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone daratumumab: Results from the ANDROMEDA study. Sanchorawala V, Palladini G, Minnema MC, Jaccard A, Lee HC, Gibbs S, et al. Am J Hematol. 2022;97(6):719–30.

• Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Sanchorawala V, Boccadoro M, Gertz M, Hegenbart U, Kastritis E, Landau H, et al. Amyloid. 2022;29(1):1–7.

• Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. N Engl J Med. 2021;385(1):46–58.
• The Clinical Impact of Proteomics in Amyloid Typing. Hill MM, Dasari S, Mollee P, Merlini G, Costello CE, Hazenberg BPC, et al. Mayo Clin Proc. 2021;96(5):1122–7.

• Response of factor X deficiency to darutumumab in the treatment of AL amyloidosis: a novel finding. Mar E, Taylor K, Mollee P. BMJ Case Rep. 2021;14(4).

• Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. Kastritis E, Leleu X, Arnulf B, Zamagni E, Cibeira MT, Kwok F, et al. J Clin Oncol. 2020;38(28):3252–60.
• The epidemiology of amyloidosis in Australia. Wisniowski B, McLeod D, Adams R, Harvey Y, Armes J, Papadimos D, et al. Amyloid. 2019;26(sup1):132–3.

• The epidemiology of amyloidosis in Queensland, Australia. Wisniowski B, McLeod DSA, Adams R, Harvey Y, Brown I, McGuire L, et al. Br J Haematol. 2019;186(6):829–36.
• Validation of the Boston University staging system in AL amyloidosis. Tomlinson R, Matigian N, Mollee P. Amyloid. 2019;26(3):125–7.

• The treatment of paraprotein-related kidney disease. Hutchison CA, Xiong F, Mollee P. Curr Opin Nephrol Hypertens. 2017 Nov;26(6):477-483

• Mass spectrometry analysis for amyloidosis typing – is the future bright for its clinical implementation? Hill MM, Mollee PN. Expert Rev Proteomics. 2017 Jul;14(7):565-566

• Cardiac amyloid imaging with ¹⁸F-florbetaben positron emission tomography: a pilot study. Law WP, Wang W, Moore P, Mollee P, Ng A. Amyloid. 2017 Mar;24(sup1):162

• Malabsorption Secondary to Gout-Induced Amyloidosis. Azzam A, Balasubramaniam R, Safa S, McIvor C, Mollee P. ACG Case Rep J. 2017 Mar 1;4:e32

• The Utility of ^99mTc-DPD Scintigraphy in the Diagnosis of Cardiac Amyloidosis: An Australian Experience. Moore PT, Burrage MK, Mackenzie E, Law WP, Korczyk D, Mollee P. Heart Lung Circ. 2017 Nov;26(11):1183-1190

• Cardiac Amyloid Imaging with 18F-Florbetaben PET: A Pilot Study. Law WP, Wang WY, Moore PT, Mollee PN, Ng AC. J Nucl Med. 2016 Nov;57(11):1733-1739

• Implementation and evaluation of amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometry. Mollee P, Boros S, Loo D, Ruelcke JE, Lakis VA, Cao KL, Renaut P, Hill MM. Clin Proteomics. 2016 Oct 27;13:3

• Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis. Mollee P, Merlini G. Clin Chem Lab Med. 2016 Jun 1;54(6):921-7

• Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Weber N, Mollee P, Augustson B, Brown R, Catley L, Gibson J, Harrison S, Ho PJ, Horvath N, Jaksic W, Joshua D, Quach H, Roberts AW, Spencer A, Szer J, Talaulikar D, To B, Zannettino A, Prince HM. Intern Med J. 2015 Apr;45(4):371-82

• How to diagnose amyloidosis. Mollee P, Renaut P, Gottlieb D, Goodman H. Intern Med J. 2014 Jan;44(1):7-17

• Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis. Mollee P, Tate J, Pretorius CJ. Clin Chem Lab Med. 2013 Dec;51(12):2303-10

• End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases. Tang W, McDonald SP, Hawley CM, Badve SV, Boudville N, Brown FG, Clayton PA, Campbell SB, de Zoysa JR, Johnson DW. Nephrol Dial Transplant. 2013 Feb;28(2):455-61

• A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis. Mollee P, Tiley C, Cunningham I, Moore J, Prince HM, Cannell P, Gibbons S, Tate J, Paul S, Mar Fan H, Gill DS. Br J Haematol. 2012 Jun;157(6):766-9

• Proteomics in molecular diagnosis: typing of amyloidosis. Loo D, Mollee PN, Renaut P, Hill MM. J Biomed Biotechnol. 2011;2011:754109

• Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. Mollee P. Clin Biochem Rev. 2009 Aug;30(3):93-103

• Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis. Morris KL, Tate JR, Gill D, Kennedy G, Wellwood J, Marlton P, Bird R, Mills AK, Mollee P. Intern Med J. 2007 Jul;37(7):456-63

• Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Tate JR, Mollee P, Dimeski G, Carter AC, Gill D. Clin Chim Acta. 2007 Feb;376(1-2):30-6

• Hereditary fibrinogen A alpha-chain amyloidosis. Lane SW, Goodman HJ, Francis L, Bofinger A, Mollee PN. Pathology. 2006 Aug;38(4):380-2